bioMérieux - 2012 Financial Results

The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met yesterday and approved the consolidated financial statements for the year ended December 31, 2012. The meeting was chaired by Jean-Luc Belingard and attended by the Statutory Auditors, who have audited the financial statements and will issue an unqualified opinion in the coming days.

“In a challenging economic environment, bioMérieux delivered commercial and financial performance in line with the objectives set early in 2012,” said Jean-Luc Belingard, Chairman and Chief Executive Officer. “Sales increased by 6.8% at constant exchange rates, while operating income before non-recurring items reached €260 million. These results attest to our competitiveness and to the validity of our strategic positioning as a leader in clinical and industrial microbiology, and as a differentiated player in the fields of immunoassays and molecular biology. In 2013, we will launch three innovative systems and pursue our international deployment. In addition, in today’s rapidly changing scientific, technological and economic environment, we will reinforce the focus of our business on our key areas of specialization.”

2012 performance: objectives met

• Sales up 6.8% at constant exchange rates
• €260 million in operating income before non-recurring items
• €134 million in free cash flow
• Robust international expansion, particularly in emerging markets, whose sales grew 17% on an organic basis and represented 29% of consolidated revenue

Reinforced strategic focus on key areas of specialization:

• Clinical microbiology
• Industrial applications
• High medical value immunoassays
• Competitiveness led by innovation, with three major market launches in 2013